ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …

Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance
to conventional therapies, including temozolomide, the most widely used chemotherapeutic …

Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet
systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies …

Purpose: Temozolomide resistance remains a major obstacle in the treatment of
glioblastoma (GBM). The combination of temozolomide with another agent could offer an …

In embryonic development and throughout life, there are some cells can exhibit phenotypic
plasticity. Phenotypic plasticity is the ability of cells to differentiate into multiple lineages. In …

Abstract Non‐thermal, intermediate frequency (100–500 kHz) electrotherapies present a
unique therapeutic strategy to treat malignant neoplasms. Here, pulsed electric fields (PEFs) …

Background ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the
blood–brain barrier. ONC201 efficacy has been shown in glioblastoma animal models and …

Recent studies indicate that signaling molecules traditionally associated with central
nervous system function play critical roles in cancer. Dopamine receptor signaling is …

Glioblastoma (GBM) is the most common intrinsic and aggressive primary brain tumor in
adults, with a median survival of approximately 15 months. GBM heterogeneity is considered …

Background After diagnosis, glioblastoma (GBM) patients undertake tremendous
psychological problems such as anxiety and depression, which may contribute to GBM …